HC Wainwright & Co. Maintains Buy Rating for Inhibikase Therapeutics: Here's What You Need To Know

By: via Benzinga
HC Wainwright & Co. has decided to maintain its Buy rating of Inhibikase Therapeutics (NASDAQ:IKT) and raise its price target from ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.